valu usd unless otherwis note
thought set-up ahead continu
view call favor risk/reward take
target follow expert tax call approach
thur includ first-tim guidanc think street number
reason two updat week add increment comfort
still need see sustain improv csca us consum
stori evolv favor direct
updat monday add comfort around first-tim guidanc
bolt-on activ new launch key turnaround yesterday
announc acquisit high ridg brand oral care
deal expect close revenu accret year
last night approv long-await gener proair partner
limit launch steadi suppli latter
back long delay teva brand sale declin
model year
number ep proair seem reason
beat lupin cipla market see updat link
approach thur given prior pre-announc link focu
first-tim guidanc year think street number
reason forecast revenu ep bn
slightli ahead bottom line also line key csca busi
bn call et id speak
manag post call
bigger catalyst upcom irish high court hear
import updat walk tax expert call
target current probabl tax liabil compris per-shar
valu stock big focu irish compon
bn biggest piec estim like total ir claim
bn per share net leverag would rise fulli
favor irish high court decis legitim expect view
ir litig could settl year-end clean
tax overhang could remov per share uncertainti repres
biggest updat near-term view
watch progress key greater sustain upsid
view still execut three thing show sustain
improv csca organ growth margin perform ii
address tax liabil irish/ir collect add
turn busi iii sell rx busi would leav
pure-play brand/stor brand consum platform could potenti
draw strateg interest watch evid progress
three thur
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base-cas scenario see stock impli
price-to-earnings ep
low-single-digit growth csca driven larg recent
ranir acquisit annual flattish excl ranir
modestli increas oper margin across platform
spend cut modest
debt pay-down excess cash share repurchas
linger overhang irish tax disput ir nopa
weigh share price
upsid case scenario see stock impli
price-to-earnings ep
mid-single-digit better organ revenu growth
oper margin expans across platform
debt pay-down excess cash re-introduc accret
favor resolut irish ir tax disput
downsid scenario see stock impli
price-to-earnings pro forma ep
meaning higher cost separ leav remain-co
earn base lower expect
market unwil re-rat remain-co higher toward
greater-than-expect liabil associ irish
stabl long-term outlook near-term uncertainti around
plan rx separ moder growth could
lead pressur valuat disclosur irish
tax assess nopa ir like add
renew consum strategi expand
tangenti find new pocket growth margin
opportun seemingli make sens also come
execut risk market uncertainti fundament like
core busi concern tie
overli ambiti forecast lofti valuat
driver thesi
csca growth like remain lower level
near term base busi eros like remain
csci add eu exposur oper margin expans
opportun high level third-parti
sourc like limit impli valuat profit
gener rx still expect separ time
valuat like dictat valu market
place remain-co consum busi
expect discount global brand peer suggest
upsid potenti limit
upsid risk success separ sale rx
drive premium asset acceler new launch
activ across over-the-counter rx fda approv new larg
over-the-counter categori switch favor quicker-than-
expect resolut irish tax disput
downsid risk slowdown core csca revenu
meaning competit entri us store brand over-the-counter
synergy/dilut rx separ expect
unfavor outcom irish us tax disput
upcom potenti catalyst updat around spin deal
gener proair time unclear potenti bolt-on
accret use capit clariti tax issu
exhibit
 incom self-car guidanc self-car guidanc guidanc excl proair other- proair upsid guidanc ep per quartertot revenu consolid sale billion growth y-i total gross profit gross sg oper incom adj oper incom oper incom interest expens millionincom tax provis incom tax expens million midpoint net incom adj net incom million ep non-gaap guidanc ep share fulli dilut share guidanc ebitda analysi net margin guidanc guidanc salesoper expens guidanc net incom exhibit
 segment build self-car guidanc incl juli ranir sale million synergi exp gross distribut oper oper sale growth sg guidanc mix profit mix incom mix self-car guidanc inclus ranir intenational gross ranir lower gm intenational rest biz neutral omdistribut other- oper oper sale growth legaci omega businessdistribut sg guidanc mix profit mix incom mix exhibit
 incom self-car guidanc self-car guidanc guidanc excl proair other- proair upsid guidanc ep per quartertot revenu consolid sale billion growth y-i total gross profit gross sg oper incom adj oper incom oper incom interest expens millionincom tax provis incom tax expens million midpoint net incom adj net incom million ep non-gaap guidanc ep share fulli dilut share guidanc ebitda analysi net margin guidanc guidanc salesoper expens guidanc net incom pharmaceuticals/specialti
price target base blend price-to-earnings ev/ebitda multipl use cy
estim assum multipl respect taken histor
averag global consum multipl price-to-earnings ev/ebitda made adjust
base company-specif attribut private-label discount earn momentum gener
busi discount litig risk collect result valuat discount
impli return price target support sector perform rate
risk rate price target
organ revenu growth consum self-car america segment soften due
weaker-than-expect over-the-counter market growth greater-than-expect price eros
delay fda approv gener drug applic result declin revenu and/
margin rx segment
unexpect meaning competit entri us store brand over-the-counter rx busi
lead store-brand over-the-counter manufactur us market share compani
also particip pharmaceut market domest intern
omega deal ad ex-u exposur often compar larg global
manufactur realiti direct comp given diversifi busi model
encompass consum healthcar brand consum healthcar rx compani
acquir brought lower tax structur royalti stream tysabri sold
royalti pharma set platform intern expans
